PMID- 29737390 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20200330 IS - 1432-1084 (Electronic) IS - 0938-7994 (Linking) VI - 28 IP - 11 DP - 2018 Nov TI - Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. PG - 4849-4859 LID - 10.1007/s00330-018-5389-z [doi] AB - OBJECTIVES: To determine if radiomic features, alone or combined with clinical data, are associated with residual tumour (RT) at surgery, and predict the risk of disease progression within 12 months (PD12) in ovarian cancer (OC) patients. METHODS: This retrospective study enrolled 101 patients according to the following inclusion parameters: cytoreductive surgery performed at our institution (9 May 2007-23 February 2016), assessment of BRCA mutational status, preoperative CT available. Radiomic features of the ovarian masses were extracted from 3D structures drawn on CT images. A phantom experiment was performed to assess the reproducibility of radiomic features. The final radiomic features included in the analysis (n = 516) were grouped into clusters using a hierarchical clustering procedure. The association of each cluster's representative radiomic feature with RT and PD12 was assessed by chi-square test. Multivariate analysis was performed using logistic regression models. P values < 0.05 were considered significant. RESULTS: Patients with values of F2-Shape/Compactness1 below the median, of F1- GrayLevelCooccurenceMatrix25/0-1InformationMeasureCorr2 below the median and of F1-GrayLevelCooccurenceMatrix25/-333-1InverseVariance above the median showed higher risk of RT (36%, 36% and 35%, respectively, as opposed to 18%, 18% and 18%). Patients with values of F4-GrayLevelRunLengthMatrix25/-333RunPercentage above the median, of F2 shape/Max3DDiameter below the median and F1-GrayLevelCooccurenceMatrix25/45-1InverseVariance above the median showed higher risk of PD12 (22%, 24% and 23%, respectively, as opposed to 6%, 5% and 6%). At multivariate analysis F2-Shape/Max3DDiameter remained significant (odds ratio (95% CI) = 11.86 (1.41-99.88)). To predict PD12, a clinical radiomics model performed better than a base clinical model. CONCLUSION: This study demonstrated significant associations between radiomic features and prognostic factors such as RT and PD12. KEY POINTS: * No residual tumour (RT) at surgery is the most important prognostic factor in OC. * Radiomic features related to mass size, randomness and homogeneity were associated with RT. * Progression of disease within 12 months (PD12) indicates worse prognosis in OC. * A model including clinical and radiomic features performed better than only-clinical model to predict PD12. FAU - Rizzo, Stefania AU - Rizzo S AUID- ORCID: 0000-0002-5151-0866 AD - Department of Radiology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. stefania.rizzo@ieo.it. FAU - Botta, Francesca AU - Botta F AD - Medical Physics, European Institute of Oncology, Milan, Italy. FAU - Raimondi, Sara AU - Raimondi S AD - Department of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. FAU - Origgi, Daniela AU - Origgi D AD - Medical Physics, European Institute of Oncology, Milan, Italy. FAU - Buscarino, Valentina AU - Buscarino V AD - Universita degli Studi di Milano, Postgraduation School in Radiodiagnostics, Milan, Italy. FAU - Colarieti, Anna AU - Colarieti A AD - Dipartimento di Medicina Interna e Specialita mediche, Universita degli Studi di Roma La Sapienza, Roma, Italy. FAU - Tomao, Federica AU - Tomao F AD - Dipartimento di scienze ginecologico ostetriche e scienze urologiche, Universita degli Studi di Roma La Sapienza, Roma, Italy. FAU - Aletti, Giovanni AU - Aletti G AD - Department of Gynecologic Oncology, European Institute of Oncology, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, Universita degli Studi di Milano, Milan, Italy. FAU - Zanagnolo, Vanna AU - Zanagnolo V AD - Department of Gynecologic Oncology, European Institute of Oncology, Milan, Italy. FAU - Del Grande, Maria AU - Del Grande M AD - Oncology Institute of Southern Switzerland, San Giovanni Hospital, 6500, Bellinzona, Switzerland. FAU - Colombo, Nicoletta AU - Colombo N AD - Department of Gynecologic Oncology, European Institute of Oncology, Milan, Italy. AD - Gynecologic Oncology Program, European Institute of Oncology and University of Milan-Bicocca, Milan, Italy. FAU - Bellomi, Massimo AU - Bellomi M AD - Department of Radiology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, Universita degli Studi di Milano, Milan, Italy. LA - eng PT - Journal Article DEP - 20180508 PL - Germany TA - Eur Radiol JT - European radiology JID - 9114774 SB - IM MH - Adult MH - Aged MH - Disease Progression MH - Female MH - Humans MH - *Imaging, Three-Dimensional MH - Middle Aged MH - Neoplasm, Residual/diagnosis MH - Ovarian Neoplasms/*diagnosis/surgery MH - Ovariectomy MH - Phantoms, Imaging MH - Preoperative Period MH - Prognosis MH - Reproducibility of Results MH - Retrospective Studies MH - Tomography, X-Ray Computed/*methods OTO - NOTNLM OT - Cancer OT - Disease progression OT - Ovary OT - Prognosis OT - Residual tumour EDAT- 2018/05/09 06:00 MHDA- 2018/12/12 06:00 CRDT- 2018/05/09 06:00 PHST- 2017/12/01 00:00 [received] PHST- 2018/02/16 00:00 [accepted] PHST- 2018/01/26 00:00 [revised] PHST- 2018/05/09 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2018/05/09 06:00 [entrez] AID - 10.1007/s00330-018-5389-z [pii] AID - 10.1007/s00330-018-5389-z [doi] PST - ppublish SO - Eur Radiol. 2018 Nov;28(11):4849-4859. doi: 10.1007/s00330-018-5389-z. Epub 2018 May 8.